Trial Profile
A DOUBLE-BLINDED, RANDOMIZED, PARALLEL, PLACEBO-CONTROLLED TRIAL OF WHARTON'S JELLY DERIVED ALLOGENEIC MESENCHYMAL STROMAL CELLS TO PRESERVE ENDOGENOUS INSULIN PRODUCTION IN ADULT PATIENTS DIAGNOSED WITH TYPE 1 DIABETES
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 May 2023
Price :
$35
*
At a glance
- Drugs Mesenchymal-stem-cell-therapy NextCell-Pharma (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors NextCell Pharma
- 24 May 2023 Results assessing whether allogeneic Wharton's jelly-derived MSCs (ProTrans) is a safe treatment for recent-onset type 1 diabetes, with the potential to preserve beta cell function, published in the Diabetologia
- 28 Mar 2023 According to a NextCell Pharma media release, article detailing the results of their phase I/II clinical trial in type I diabetes accepted in the peer-reviewed journal Diabetologia.
- 28 Mar 2023 Results published in the NextCell Pharma Media Release